罂粟碱联合立体定向放疗治疗肺肿瘤缺氧增敏的I期试验
这项I期试验评估了在肺肿瘤立体定向体部放疗(SBRT)前给予罂粟碱(PPV)作为缺氧放射增敏剂的安全性和可行性。
要点
- PPV联合SBRT在肺肿瘤患者中可行且安全,最大耐受剂量至少为2 mg/kg。
- DL2(2 mg/kg)的剂量限制性毒性后验估计为0.17(95%CI 0.01–0.53)。
- 2年局部、区域和远处控制率分别为100%、94%和82%。
核心结论
- PPV作为缺氧放射增敏剂联合SBRT治疗肺肿瘤可行且安全,最大耐受剂量至少为2 mg/kg,鼓励进一步研究其肿瘤选择性放射增敏作用。
研究设计与样本
- IRB批准的I期临床试验,采用贝叶斯最优区间(BOIN)设计,纳入适合SBRT(50 Gy/4或5次)的早期非小细胞肺癌或局限性肺转移患者。
- PPV在每次SBRT前30–90分钟给药,设3个剂量水平:0.5 mg/kg(DL-1)、1 mg/kg(DL1)、2 mg/kg(DL2)。
主要发现
- 18例可评估患者中,7例为早期非小细胞肺癌,2例为转移性非小细胞肺癌,8例为其他组织学类型的肺转移。
- 最大耐受剂量确定为DL2(2 mg/kg),剂量限制性毒性后验估计为0.17(95%CI 0.01–0.53)。
- 2年局部、区域和远处控制率分别为100%、94%和82%。
关键数值与推荐
- PPV剂量水平:0.5 mg/kg(DL-1)、1 mg/kg(DL1)、2 mg/kg(DL2),每次SBRT前30–90分钟给药。
- SBRT剂量:50 Gy分4或5次。
- 最大耐受剂量为DL2(2 mg/kg),剂量限制性毒性后验估计0.17(95%CI 0.01–0.53)。
临床怎么用
- 对于适合SBRT的早期非小细胞肺癌或肺转移患者,可考虑在SBRT前30–90分钟给予PPV 2 mg/kg作为缺氧放射增敏剂,但需在临床试验框架内进一步验证。
局限性
- I期试验样本量小(18例可评估),主要目的是评估安全性和可行性,疗效结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tumor hypoxia has been recognized as a barrier to effective radiotherapy. Preclinical work identified the FDA approved smooth muscle relaxant papaverine (PPV) as having an "off target" activity as a mitochondrial inhibitor that reduces hypoxia and radiosensitizes model tumors. METHODS: We conducted an IRB-approved phase 1 clinical trial to evaluate safety and feasibility of adding PPV to stereotactic body radiation therapy (SBRT) for tumors of the lung. Eligible patients with early-stage non-small cell lung cancer (NSCLC) or limited lung metastases who were candidates for SBRT (50 Gy in 4 or 5 fractions) were enrolled. Based on a Bayesian Optimal Interval (BOIN) design, patients were allocated to receive PPV 30-90 minutes prior to each SBRT fraction at 3 dose levels (DL): 0.5 mg/kg (DL-1), 1 mg/kg (DL1), or 2mg/kg (DL2). RESULTS: Nineteen patients enrolled and 18 completed study treatment and were evaluable, with a median follow up of 33.4 months. Among 18 evaluable patients, 7 had early-stage NSCLC, 2 had metastatic NSCLC, and 8 had lung metastases from other histologies. The maximum tolerated dose (MTD) was determined to be DL2, which had a dose limiting toxicity (DLT) rate posterior estimate of 0.17 (95% CI 0.01 to 0.53). The 2-year controls rates for local, regional and distant control were 100%, 94% and 82%, respectively. CONCLUSIONS: We demonstrate the feasibility and safety of PPV as a hypoxic radiosensitizer for SBRT. The MTD for this patient population is at least 2 mg/kg of PPV. Encouraging clinical results indicate that further investigation of PPV's utility as a tumor-selective radiosensitizer is warranted.
引用
- Brownstein J, Williams T, Xu-Welliver M, et al. A Phase 1 Trial Investigating the Addition of Papaverine to Stereotactic Body Radiotherapy (SBRT) for Hypoxic Radiosensitization of Lung Tumors. Int J Radiat Oncol Biol Phys. 2026. PMID: 42913863. doi:10.1016/j.ijrobp.2026.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。